Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT03271632
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • CAR T cells — BIOLOGICAL
    Infusion of multi-CAR T cells

Study Details

The aim of this clinical trial is to assess the feasibility, safety and efficacy of autologous CAR T cell immunotherapy targeting multiple cancer cell surface antigens in relapsed and refractory multiple myeloma patients. Another goal of the study is to learn more about the persistence and function of CAR T cells in the body.

Key Dates

First listed
Sep 5, 2017
Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single arm
    CAR T cells to treat MM

Primary Outcome Measure

Percentage of patients with treatment related adverse effect [ Time Frame: 1 month ]

Central Contacts

Find similar trials

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials

Related Studies